

Chuan-bao Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8433347/publications.pdf>

Version: 2024-02-01

114
papers

5,917
citations

101384

36
h-index

85405

71
g-index

116
all docs

116
docs citations

116
times ranked

7404
citing authors

#	ARTICLE	IF	CITATIONS
1	Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. <i>Journal of Neurosurgery</i> , 2022, 136, 67-75.	0.9	15
2	Comprehensive analysis of the LncRNAs, MiRNAs, and MRNAs acting within the competing endogenous RNA network of LGG. <i>Genetica</i> , 2022, 150, 41.	0.5	1
3	Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma. <i>Chinese Neurosurgical Journal</i> , 2022, 8, 6.	0.3	0
4	Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma. <i>Aging</i> , 2022, 14, 2320-2334.	1.4	7
5	Expression changes in ion channel and immunity genes are associated with glioma-related epilepsy in patients with diffuse gliomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2793-2802.	1.2	2
6	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	3.2	194
7	Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2589-2600.	2.0	5
8	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 617-628.	1.9	7
9	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12.	3.0	439
10	MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 566492.	1.3	9
11	New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 682535.	1.1	3
12	T-Cell Exhaustion Status Under High and Low Levels of Hypoxia-Inducible Factor 1 α Expression in Glioma. <i>Frontiers in Pharmacology</i> , 2021, 12, 711772.	1.6	13
13	Consistency of pituitary adenomas: Amounts of collagen types I and III and the predictive value of T2WI MRI. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1255.	0.8	4
14	Comparative profiling of immune genes improves the prognoses of lower grade gliomas. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	5
15	CPNE3 regulates the cell proliferation and apoptosis in human Glioblastoma via the activation of PI3K/AKT signaling pathway. <i>Journal of Cancer</i> , 2021, 12, 7277-7286.	1.2	1
16	Targeted exome sequencing for the identification of common mutational signatures and potential driver mutations for brain metastases and prognosis. <i>Oncology Letters</i> , 2021, 21, 179.	0.8	0
17	Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. <i>Bioengineered</i> , 2021, 12, 10791-10798.	1.4	9
18	CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7315-7329.	1.6	15

#	ARTICLE	IF	CITATIONS
19	<i>PABPC1</i> relevant bioinformatic profiling and prognostic value in gliomas. <i>Future Oncology</i> , 2020, 16, 4279-4288.	1.1	14
20	Characterization and prognostic significance of alternative splicing events in lower-grade diffuse gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13171-13180.	1.6	4
21	Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 473-487.	1.4	18
22	Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa098.	0.4	4
23	Identification of PIEZO1 as a potential prognostic marker in gliomas. <i>Scientific Reports</i> , 2020, 10, 16121.	1.6	39
24	Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 538.	1.8	105
25	Prognostic value of a nine-gene signature in glioma patients based on tumor-associated macrophages expression profiling. <i>Clinical Immunology</i> , 2020, 216, 108430.	1.4	18
26	Hemangiopericytomas: Spatial Intracranial Location in a Voxel-Based Mapping Study. <i>Journal of Neuroimaging</i> , 2020, 30, 370-377.	1.0	1
27	Identification of a Glycolysis-Related LncRNA Signature to Predict Survival in Diffuse Glioma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 597877.	1.3	12
28	Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 90-104.	0.0	9
29	Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , 2020, 20, 187.	0.8	0
30	Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	1
31	Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. <i>Frontiers in Immunology</i> , 2019, 10, 1756.	2.2	35
32	Predicting chromosome 1p/19q codeletion by RNA expression profile: a comparison of current prediction models. <i>Aging</i> , 2019, 11, 974-985.	1.4	5
33	PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PCK1. <i>Molecular Cell</i> , 2019, 76, 516-527.e7.	4.5	113
34	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. <i>OncImmunology</i> , 2019, 8, e1541535.	2.1	32
35	Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 876-883.	1.9	27
36	Differentiation of glioblastoma from solitary brain metastases using radiomic machine-learning classifiers. <i>Cancer Letters</i> , 2019, 451, 128-135.	3.2	128

#	ARTICLE	IF	CITATIONS
37	Predicting the likelihood of early recurrence based on mRNA sequencing of pituitary adenomas. <i>Gland Surgery</i> , 2019, 8, 648-656.	0.5	4
38	MR imaging based fractal analysis for differentiating primary CNS lymphoma and glioblastoma. <i>European Radiology</i> , 2019, 29, 1348-1354.	2.3	18
39	ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. <i>Oncolmmunology</i> , 2019, 8, e1534038.	2.1	39
40	EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. <i>Molecular Cell</i> , 2018, 70, 197-210.e7.	4.5	116
41	Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. <i>Oncolmmunology</i> , 2018, 7, e1434466.	2.1	53
42	CLDN5 affects lncRNAs acting as ceRNA dynamics contributing to regulating blood-brain barrier permeability in tumor brain metastasis. <i>Oncology Reports</i> , 2018, 39, 1441-1453.	1.2	16
43	MiR-134, epigenetically silenced in gliomas, could mitigate the malignant phenotype by targeting KRAS. <i>Carcinogenesis</i> , 2018, 39, 389-396.	1.3	6
44	PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. <i>Oncolmmunology</i> , 2018, 7, e1382792.	2.1	37
45	Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 127-137.	1.4	66
46	Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas. <i>Future Oncology</i> , 2018, 14, 545-552.	1.1	1
47	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , 2018, 9, 1190.	2.7	42
48	miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas. <i>Oncolmmunology</i> , 2018, 7, e1510277.	2.1	17
49	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. <i>Cell</i> , 2018, 175, 1665-1678.e18.	13.5	250
50	Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. <i>Cancer Science</i> , 2018, 109, 2697-2705.	1.7	73
51	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. <i>Disease Markers</i> , 2018, 2018, 1-8.	0.6	9
52	Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. <i>Journal of Neuroinflammation</i> , 2018, 15, 145.	3.1	15
53	CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. <i>EBioMedicine</i> , 2018, 35, 233-243.	2.7	97
54	Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. <i>Aging</i> , 2018, 10, 1977-1988.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. <i>Journal of Neurosurgery</i> , 2017, 126, 249-259.	0.9	19
56	Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status. <i>Journal of Neuro-Oncology</i> , 2017, 132, 207-218.	1.4	16
57	Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy. <i>Molecular Cell</i> , 2017, 65, 917-931.e6.	4.5	190
58	Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. <i>Neuro-Oncology</i> , 2017, 19, 736-738.	0.6	20
59	miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF- κ B pathways in glioblastoma. <i>Cancer Letters</i> , 2017, 396, 1-9.	3.2	50
60	Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. <i>Scientific Data</i> , 2017, 4, 170024.	2.4	208
61	Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. <i>Nature Communications</i> , 2017, 8, 949.	5.8	191
62	Relationship between necrotic patterns in glioblastoma and patient survival: fractal dimension and lacunarity analyses using magnetic resonance imaging. <i>Scientific Reports</i> , 2017, 7, 8302.	1.6	55
63	Tumor Purity as an Underlying Key Factor in Glioma. <i>Clinical Cancer Research</i> , 2017, 23, 6279-6291.	3.2	372
64	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>Oncolmmunology</i> , 2017, 6, e1328339.	2.1	114
65	The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. <i>Clinical Cancer Research</i> , 2017, 23, 2177-2185.	3.2	12
66	Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. <i>Molecular Neurobiology</i> , 2017, 54, 5996-6005.	1.9	41
67	Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 69-75.	1.9	32
68	Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. <i>Oncotarget</i> , 2017, 8, 42974-42982.	0.8	8
69	Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma. <i>Oncotarget</i> , 2017, 8, 53110-53123.	0.8	55
70	A PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance. <i>Oncotarget</i> , 2017, 8, 85794-85803.	0.8	8
71	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. <i>Oncotarget</i> , 2016, 7, 16384-16395.	0.8	53
72	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , 2016, 7, 45005-45014.	0.8	10

#	ARTICLE	IF	CITATIONS
73	ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. <i>Oncoscience</i> , 2016, 3, 258-265.	0.9	42
74	ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1276.	1.8	27
75	FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. <i>Oncotarget</i> , 2016, 7, 84587-84593.	0.8	10
76	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. <i>Oncolmmunology</i> , 2016, 5, e1196310.	2.1	176
77	Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 169-176.	1.5	3
78	Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 128, 455-462.	1.4	9
79	Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas. <i>Journal of Neuroimmunology</i> , 2016, 294, 27-31.	1.1	11
80	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	3.2	448
81	Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. <i>Scientific Reports</i> , 2016, 6, 21141.	1.6	29
82	Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. <i>Neurology</i> , 2016, 86, 2226-2234.	1.5	234
83	Clinicopathological factors predictive of postoperative seizures in patients with gliomas. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016, 35, 93-99.	0.9	31
84	Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. <i>Journal of Neurosurgery</i> , 2016, 125, 7-16.	0.9	20
85	Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases. <i>Oncotarget</i> , 2016, 7, 59098-59114.	0.8	10
86	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. <i>Oncotarget</i> , 2016, 7, 80091-80100.	0.8	2
87	Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. <i>Oncotarget</i> , 2016, 7, 73971-73983.	0.8	22
88	KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4. <i>Oncotarget</i> , 2016, 7, 24646-24655.	0.8	33
89	Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 127.	3.5	17
90	Identification of a 6-Cytokine Prognostic Signature in Patients with Primary Glioblastoma Harboring M2 Microglia/Macrophage Phenotype Relevance. <i>PLoS ONE</i> , 2015, 10, e0126022.	1.1	59

#	ARTICLE	IF	CITATIONS
91	Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. <i>Oncology Reports</i> , 2015, 34, 1503-1509.	1.2	16
92	Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. <i>Cancer Letters</i> , 2015, 357, 566-574.	3.2	25
93	High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype. <i>Journal of Neuro-Oncology</i> , 2015, 122, 43-51.	1.4	29
94	Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis. <i>Journal of Neuro-Oncology</i> , 2015, 121, 609-616.	1.4	16
95	HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. <i>Journal of Neuro-Oncology</i> , 2015, 122, 303-312.	1.4	36
96	Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. <i>PLoS ONE</i> , 2015, 10, e0130872.	1.1	28
97	HOTAIR is a therapeutic target in glioblastoma. <i>Oncotarget</i> , 2015, 6, 8353-8365.	0.8	105
98	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. <i>Oncotarget</i> , 2015, 6, 7318-7324.	0.8	40
99	Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. <i>Oncotarget</i> , 2015, 6, 18105-18115.	0.8	48
100	A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. <i>Oncotarget</i> , 2015, 6, 29285-29295.	0.8	49
101	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , 2015, 6, 36643-36651.	0.8	39
102	Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. <i>Oncotarget</i> , 2015, 6, 38257-38269.	0.8	11
103	Rab27a Was Identified as a Prognostic Biomaker by mRNA Profiling, Correlated with Malignant Progression and Subtype Preference in Gliomas. <i>PLoS ONE</i> , 2014, 9, e89782.	1.1	22
104	MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. <i>Oncotarget</i> , 2014, 5, 12908-12915.	0.8	54
105	Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2014, 120, 331-337.	1.4	21
106	Expression of SPRR3 is associated with tumor cell proliferation and invasion in glioblastoma multiforme. <i>Oncology Letters</i> , 2014, 7, 427-432.	0.8	18
107	Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 45-51.	1.2	57
108	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. <i>Genome Research</i> , 2014, 24, 1765-1773.	2.4	316

#	ARTICLE	IF	CITATIONS
109	Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma. <i>Oncology Reports</i> , 2014, 32, 250-260.	1.2	12
110	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. <i>Oncotarget</i> , 2014, 5, 2551-2561.	0.8	61
111	Multidimensional analysis of gene expression reveals TGFBI1-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014, 5, 12593-12606.	0.8	36
112	BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. <i>Journal of Translational Medicine</i> , 2013, 11, 100.	1.8	32
113	Progress on molecular biomarkers and classification of malignant gliomas. <i>Frontiers of Medicine</i> , 2013, 7, 150-156.	1.5	21
114	Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma. <i>Oncology Reports</i> , 2013, 30, 2089-2096.	1.2	13